Back

Five-year cardiovascular outcomes in patients with chronic myeloid leukemia treated with imatinib, dasatinib or nilotinib: data from a large multinational collaborative network

27 August 2022 (10:15 - 11:00)
Organised by:
Congress Presentation Part of: Cardio-oncology 3 Cardio-Oncology ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Rafael Belo Nunes

Hospital Alemao Oswaldo Cruz, Sao Paulo (Brazil)

7 More presentations in this session

Presentation thumbnail
Low-dose anticoagulation for peripheral deep vein thrombosis of the lower extremities in cancer patients
Doctor A. Nonaka (Akashi, JP)
Abstract Slides
Presentation thumbnail
Cardiorespiratory fitness and left ventricular function in breast cancer survivors a decade after Epirubicin treatment
Miss M. Saeter (Oslo, NO)
Abstract Slides
Presentation thumbnail
Cancer as a risk factor for physical dysfunction and poor prognosis in patients with cardiovascular disease
Mr T. Miki (Sagamihara, JP)
Abstract Slides
Presentation thumbnail
Coronary calcification is independently associated with major adverse cardiovascular events in men with recurrent prostate cancer while aortic calcification is not
Doctor A. Som (Saint Louis, US)
Abstract Slides
Presentation thumbnail
Cardioprotection against cardiac dysfunction from breast cancer chemotherapy: a bayesian and frequentist network meta-analysis of randomised controlled trials
Doctor P. Jeyaprakash (Sydney, AU)
Abstract Slides

Access the full session

Session thumbnail
Cardio-oncology 3

The Event

Event poster

ESC Congress 2022

27 August 2022 10:15 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources